AcelRx Pharmaceuticals Inc (ACRX):医療機器:M&Aディール及び事業提携情報

◆英語タイトル:AcelRx Pharmaceuticals Inc (ACRX) - Medical Equipment - Deals and Alliances Profile
◆商品コード:DATA904C7148
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:38
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:医療機器
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
AcelRx Pharmaceuticals Inc (AcelRx), is a specialty pharmaceutical company that develops and commercializes drugs for the treatment of pain. The company’s lead product candidate, Dsuvia (known as Dzuveo outside the US), is a single sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. Its pipeline also includes Zalviso, a drug and device combination product for management of moderate to severe acute pain in adults. AcelRx developed a proprietary, non-invasive, sublingual formulation technology to deliver its highly lipophilic drugs. The company commercializes its EC approved Zalviso under license agreement with Grunenthal in various European Union countries and Australia. AcelRx is headquartered in Redwood City, California, the US.

AcelRx Pharmaceuticals Inc (ACRX) – Medical Equipment – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
AcelRx Pharmaceuticals Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 5
AcelRx Pharmaceuticals Inc, Medical Equipment Deals By Type, 2012 to YTD 2018 6
AcelRx Pharmaceuticals Inc, Medical Equipment, Deals By Region, 2012 to YTD 2018 7
AcelRx Pharmaceuticals Inc, Medical Equipment, Deals By Market, 2012 to YTD 2018 8
AcelRx Pharmaceuticals Inc, Medical Equipment, Deals Summary, 2012 to YTD 2018 9
AcelRx Pharmaceuticals Inc, Medical Equipment, Deal Details 10
Private Equity 10
Leerink Revelation and Industry Ventures Acquire Stake in AcelRx Pharma 10
Partnerships 11
AcelRx Pharma Amends Commercialization Agreement With Grunenthal For Zalviso 11
Equity Offering 12
AcelRx Pharma Raises USD23 Million in Public Offering of Shares 12
AcelRx Pharma Completes Public Offering Of Shares For US$51 Million 14
AcelRx Pharma Completes Underwriters’ Exercise Of Over-Allotment Option For US$6 Million 16
AcelRx Pharma Completes Private Placement Of Units For US$10 Million 18
Asset Transactions 19
PDL BioPharma Acquires Portion of Zalviso Royalty Rights from AcelRx Pharma for USD65 Million 19
AcelRx Pharmaceuticals Inc – Key Competitors 21
AcelRx Pharmaceuticals Inc – Key Employees 22
AcelRx Pharmaceuticals Inc – Locations And Subsidiaries 23
Head Office 23
Other Locations & Subsidiaries 23
Recent Developments 24
Financial Announcements 24
Aug 02, 2018: AcelRx Pharmaceuticals reports second quarter 2018 financial results 24
May 09, 2018: AcelRx Pharmaceuticals Reports First Quarter 2018 Financial Results 25
Mar 08, 2018: AcelRx Pharmaceuticals Reports Fourth Quarter 2017 Financial Results 26
Nov 09, 2017: AcelRx Pharmaceuticals Reports Third Quarter 2017 Financial Results 27
Aug 01, 2017: AcelRx Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Corporate Update 28
May 08, 2017: AcelRx Pharmaceuticals Reports First Quarter 2017 Financial Results and Provides Corporate Update 30
Mar 02, 2017: AcelRx Pharmaceuticals Reports Fourth Quarter and Year End 2016 Financial Results 32
Corporate Communications 34
Mar 27, 2018: AcelRx Pharmaceuticals Names John Saia As General Counsel 34
Jul 19, 2017: AcelRx Pharmaceuticals Appoints Raffi Asadorian as Chief Financial Officer 35
Feb 16, 2017: AcelRx Pharmaceuticals Appoints Vincent J. Angotti Chief Executive Officer 36
Legal and Regulatory 37
Oct 12, 2018: AcelRx Pharmaceuticals Stock Trading Halted 37
Appendix 38
Methodology 38
About GlobalData 38
Contact Us 38
Disclaimer 38

List of Tables
AcelRx Pharmaceuticals Inc, Medical Equipment, Key Facts, 2017 2
AcelRx Pharmaceuticals Inc, Medical Equipment, Deals Summary, 2012 to YTD 2018 2
AcelRx Pharmaceuticals Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 5
AcelRx Pharmaceuticals Inc, Medical Equipment Deals By Type, 2012 to YTD 2018 6
AcelRx Pharmaceuticals Inc, Medical Equipment, Deals By Region, 2012 to YTD 2018 7
AcelRx Pharmaceuticals Inc, Deals By Market, 2012 to YTD 2018 8
AcelRx Pharmaceuticals Inc, Medical Equipment, Deals Summary, 2012 to YTD 2018 9
Leerink Revelation and Industry Ventures Acquire Stake in AcelRx Pharma 10
AcelRx Pharma Amends Commercialization Agreement With Grunenthal For Zalviso 11
AcelRx Pharma Raises USD23 Million in Public Offering of Shares 12
AcelRx Pharma Completes Public Offering Of Shares For US$51 Million 14
AcelRx Pharma Completes Underwriters' Exercise Of Over-Allotment Option For US$6 Million 16
AcelRx Pharma Completes Private Placement Of Units For US$10 Million 18
PDL BioPharma Acquires Portion of Zalviso Royalty Rights from AcelRx Pharma for USD65 Million 19
AcelRx Pharmaceuticals Inc, Key Competitors 21
AcelRx Pharmaceuticals Inc, Key Employees 22
AcelRx Pharmaceuticals Inc, Subsidiaries 23

List of Figures
AcelRx Pharmaceuticals Inc, Medical Equipment, Deals by Type, 2012 to YTD 2018 2
AcelRx Pharmaceuticals Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 2
AcelRx Pharmaceuticals Inc, Medical Equipment, Deals By Region, 2012 to YTD 2018 2
AcelRx Pharmaceuticals Inc, Medical Equipment, Deals By Market, 2012 to YTD 2018 2
AcelRx Pharmaceuticals Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 5
AcelRx Pharmaceuticals Inc, Medical Equipment, Deals by Type, 2012 to YTD 2018 6
AcelRx Pharmaceuticals Inc, Medical Equipment, Deals By Region, 2012 to YTD 2018 7
AcelRx Pharmaceuticals Inc, Medical Equipment, Deals by Market, 2012 to YTD 2018 8

★海外企業調査レポート[AcelRx Pharmaceuticals Inc (ACRX):医療機器:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Chembio Diagnostic Inc (CEMI):企業の財務・戦略的SWOT分析
    Chembio Diagnostic Inc (CEMI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • T3D Therapeutics Inc-製薬・医療分野:企業M&A・提携分析
    Summary T3D Therapeutics Inc (T3D) is a developer of solutions for the treatment of Alzheimer’s disease and Mild Cognitive Impairment. The company’s pipeline product include T3D-959, an optimal disease remedial therapeutic for the treatment of Alzheimer’s disease. It provides a potential to improve …
  • Nokia Corp (NOKIA):企業の財務・戦略的SWOT分析
    Nokia Corp (NOKIA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • Capital Properties Inc (CPTP):企業の財務・戦略的SWOT分析
    Summary Capital Properties Inc (Capital Properties) is a real estate company that acquires, operates, develops, and manages real estate properties. The company's services include real estate management, investment, and development and petroleum storage operations with lease interests in downtown pro …
  • Centre for Drug Design and Discovery:製薬・医療:M&Aディール及び事業提携情報
    Summary Centre for Drug Design and Discovery (CD3) is a biomedical research institution that discovers new small molecule drugs. The institution operates as an investment fund and technology transfer platform to promote the discovery and development of medicines for all kinds of diseases. It provide …
  • IBEX Technologies Inc (IBT):企業の財務・戦略的SWOT分析
    Summary IBEX Technologies Inc (IBEX) is a manufacturer and marketer of high-purity proprietary enzymes and recombinant from flavobacterium heparinum. The company provides enzymes such as heparinase I, heparinase II, heparinase III, chondroitinase AC and chondroitinase B. Its assays allow for the stu …
  • Husky Energy Inc (HSE):石油・ガス:M&Aディール及び事業提携情報
    Summary Husky Energy Inc (Husky) is an integrated energy company. It operates across the oil and gas value chain. Its upstream operations include the exploration, development and production of crude oil, bitumen, natural gas and natural gas liquids (NGL). Its midstream operations include pipeline tr …
  • Farbest-Tallman Foods Corp.:企業の戦略・SWOT・財務情報
    Farbest-Tallman Foods Corp. - Strategy, SWOT and Corporate Finance Report Summary Farbest-Tallman Foods Corp. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Diageo plc:企業の戦略・SWOT・財務情報
    Diageo plc - Strategy, SWOT and Corporate Finance Report Summary Diageo plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • Fusion Telecommunications International, Inc.:企業のM&A・事業提携・投資動向
    Fusion Telecommunications International, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Fusion Telecommunications International, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, …
  • Engro Corp Ltd (ENGRO)
    Engro Corp Ltd (ENGRO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company
  • EVN AG:企業の発電所・SWOT分析2018
    EVN AG - Power Plants and SWOT Analysis, 2018 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key employees (executives) …
  • Recipharm AB (RECI B):製薬・医療:M&Aディール及び事業提携情報
    Summary Recipharm AB (Recipharm) is a contract development and manufacturing organization (CDMO) that offers manufacturing, and development and technology services. The organization's manufacturing segment provides contract manufacturing of pharmaceuticals such as semi-solids, and oral liquids, soli …
  • Prothena Corp Plc (PRTA)-製薬・医療分野:企業M&A・提携分析
    Summary Prothena Corp Plc (Prothena) is a biotechnology company that discovers, develops and markets novel antibodies that are indicated for the treatment of diseases associated with amyloid or cell adhesion. The company develops monoclonal antibodies directed specifically at disease-causing protein …
  • CIRFOOD Cooperativa Italiana di Ristorazione s.c.:企業の戦略・SWOT・財務情報
    CIRFOOD Cooperativa Italiana di Ristorazione s.c. - Strategy, SWOT and Corporate Finance Report Summary CIRFOOD Cooperativa Italiana di Ristorazione s.c. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structur …
  • McAfee, Inc.:企業の戦略的SWOT分析
    McAfee, Inc. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • Ferrellgas Partners LP (FGP):石油・ガス:M&Aディール及び事業提携情報
    Summary Ferrellgas Partners LP (Ferrellgas) is an oil and gas company that supplies propane and related equipment. The company provides transportation, wholesale marketing, and distribution of propane. It also carries out selling refined fuels and feedstocks. Ferrellgas provides propane crop drying, …
  • Aoyama Trading Co., Ltd.
    Aoyama Trading Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Aoyama Trading Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Modus Therapeutics Holding AB-製薬・医療分野:企業M&A・提携分析
    Summary Modus Therapeutics Holding AB (Modus), formerly known as Dilaforette Holding AB, is a biotechnology company that focuses on the development of sevuparin, a proprietary polysaccharide drug for the treatment of sickle cell disease (SCD). Modus Therapeutics Holding AB - Pharmaceuticals & Health …
  • OncBioMune Pharmaceuticals Inc (OBMP):企業の財務・戦略的SWOT分析
    Summary OncBioMune Pharmaceuticals Inc (OncBioMune), formerly Quint Media Inc is a biopharmaceutical company that develops novel cancer immunotherapy products. The company’s products comprise biosimilars and vaccines developed for cancer types such as renal, breast, prostrate, and ovarian cancer. It …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆